Drug intelligence / Profile preview

thybetaxor

Development stage: Phase 2
Lead developer: Cascade Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Thybetaxor (CS060380) is a small molecule thyroid hormone receptor β (THRβ) agonist developed by Cascade Technologies (also known as Cascade Pharmaceuticals) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). As a selective thyromimetic, it is designed to target the THRβ nuclear receptor in the liver to reduce hepatic fat accumulation and improve metabolic parameters. The drug is engineered for high selectivity for the β isoform over the α isoform to minimize systemic thyroid hormone-related side effects, particularly those affecting the cardiovascular system and bone density. Thybetaxor is currently in Phase 1 clinical development.

Other names: Thybetaxor

Targets

THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on thybetaxor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thybetaxor.

Explore the full profile